Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Pharmacol., 21 November 2025

Sec. Ethnopharmacology

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1701287

Correction: Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway

This article is a correction to:

  1. Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway

    1. Read original article
Yuche Wu,&#x;Yuche Wu1,2†Bing Wang&#x;Bing Wang3†Xuwen Mao&#x;Xuwen Mao4†Wei ChenWei Chen2Haji Akber Aisa Haji Akber Aisa1*
  • 1Xinjiang Technical Institute of Physics and Chemistry Chinese Academy of Sciences, Urumqi, Xinjiang, China
  • 2Xinjiang Huashidan Pharmaceutical Co., Ltd., Urumqi, Xinjiang, China
  • 3The Fourth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
  • 4College of Pharmacy, Xinjiang Medical University, Urumqi, Xinjiang, China

A Correction on
Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway

by Wu Y, Wang B, Mao X, Chen W and Akber Aisa H (2025). Front. Pharmacol. 16:1526952. doi: 10.3389/fphar.2025.1526952

Affiliation 4 ‘Xinjiang Huashidan Pharmaceutical Co., Ltd., Urumqi, Xinjiang, China’ was renumbered as Affiliation 2.

Affiliation 2 was erroneously omitted for author Yuche Wu. The conflict of interest statement has been corrected to “Authors YW and WC were employed by Xinjiang Huashidan Pharmaceutical Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: harmine derivative B-9-3, non-small cell lung cancer, apoptosis, angiogenesis, VEGFA/PI3K/AKT

Citation: Wu Y, Wang B, Mao X, Chen W and Aisa HA (2025) Correction: Harmine derivative B-9-3 inhibits non-small cell lung cancer via the VEGFA/PI3K/AKT pathway. Front. Pharmacol. 16:1701287. doi: 10.3389/fphar.2025.1701287

Received: 27 October 2025; Accepted: 28 October 2025;
Published: 21 November 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Wu, Wang, Mao, Chen and Aisa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Haji Akber Aisa, c3VubnljaGFvcmFuQDEyNi5jb20=

†These authors have contributed equally to this work and share first authorship

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.